<!DOCTYPE html>

<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/ -->
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
	<meta charset="utf-8" />

	<!-- Set the viewport width to device width for mobile -->
	<meta name="viewport" content="width=device-width" />

	<title>Practice Network : Story of the week</title>

	<!-- Included CSS Files -->
<!-- FontDeck
<link rel="stylesheet" href="http://f.fontdeck.com/s/css/l4MsFun30OJhB9DTDGcb8JQSAOQ/practicenetwork-foundation/22889.css" type="text/css" /> 
-->

	<link rel="stylesheet" href="assets/css/app.css">
	<link rel="stylesheet" href="assets/css/font-awesome.css">
	<link rel="stylesheet" href="assets/css/fc-webicons.css">
	<link rel="stylesheet" href="assets/css/foundation-icons-general.css">

	<script src="assets/js/foundation/modernizr.foundation.js"></script>

	<!-- IE Fix for HTML5 Tags -->
	<!--[if lt IE 9]>
		<script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
	<![endif]-->

</head>
	<body id="page" class="update off-canvas slide-nav story-of-the-week">
	<div class="container">
		<nav id="topMenu" role="navigation">
			<ul id="nav" class="nav-bar">
				<li class="active"><a href="update.html">update</a></li>
				<li><a href="explore.html">Explore</a></li>
				<li><a href="learn.html">Learn</a></li>
			</ul>
		</nav>

		<div id="page-leaderboard">
			<div class="ad centered eight columns hide-for-small">
				<img src="http://placehold.it/728x90" class="ad" title="ad" />
			</div><!--/.ad-->
		</div><!--/#page-leaderboard-->
		<header id="header" class="page-header">
		  <div class="site-branding">
		    <h1 id="site-title"><a href="http://zurb.com/playground/">OncologySTAT</a></h1>
		  </div><!--/.site-branding-->
		  <div class="eight columns">
		    <nav id="menu" role="navigation" class="hide-for-small main-nav">
    			<ul id="mainNav" class="nav-bar">
						<li class="active"><a href="update.html">update</a></li>
						<li><a href="explore.html">Explore</a></li>
						<li><a href="learn.html">Learn</a></li>
    			</ul>
    		</nav><!--/#menu-->
		  </div><!--/.eight columns-->
		</header><!--/.page-header-->

	<div class="page-content">
		<div class="row">
			<div class="show-for-small">
				<div class="four columns mobile-two"><a class='menu-button button' id="menuButton" href="#menu">Menu</a></div>
				<div class="four columns mobile-two"><a class='sidebar-button button' id="sidebarButton" href="#sidebar" >Extra</a></div>
			</div><!--/.show-for-small-->
		</div><!--/.row-->
	<section role="main">
<div class="item-container">
<article class="type-blog item-id">
	<header class="item-header">
		<hgroup>
			<h1 class="item-title">Article Title</h1>
			<h2 class="item-subtitle">Article Subtitle - Optional</h2>
		</hgroup>
		<div class="meta pub-meta">
			<time class="meta pub-pubdate" datetime="2012-03-05">March 5th, 2012</time>
			<span class="meta pub-attribution">Howard Scher, MD</span>
		</div>
		<div class="row-fluid">
		<div class="author-meta span6"><!-- Note: cleanup author meta vcard markup-->
			<div class="author vcard">
				<p class="meta author-role role">Expert</p>
				<figure class="author-photo">
					<img class="photo" src="http://placehold.it/100x100"/>
					<figcaption>
						<p class="fn n"><a class="url uid" href="#"><span class="given-name">Author</span> <span class="family-name">Name</span>, <span class="honorific-suffix">MD</span></a></p>
						<p class="author-position"><span class="author-title title">Author's current title</span>, <span class="organization-name">organization name</span></p>
					</figcaption>
				</figure>
			</div><!--/.author-->
		</div><!--/.author-meta-->
		<div class="item-description span4">
			<p>In this commentary, Dr. Scher discusses his research on a novel androgen receptor signaling inhibitor, MDV3100, which was shown to improve survival in a post-chemotherapy population of men with progressive castration-resistant prostate cancer (CRPC).</p>
		</div>
		</div><!--/.row-fluid-->
			<div class="meta taxonomy-meta"><i class="icon-tags"></i>
			<p>Find more items about these cancer types:</p>
			<ul class="tag-list">
			<li class="">cancer types:</li>
				<li class="list-header">
					<a class="label label-tag" href="#">Prostate</a>
				</li>
			</ul>
			
			<ul class="tag-list">
			<li class="">Secondary Term:</li>
				<li>
					<a class="label label-tag" href="#">tag</a>
				</li>
			</ul>
			
			<ul class="tag-list">
			<li class="">supportive Care:</li>
				<li>
					<a class="label label-tag" href="#">tag</a>
				</li>
			</ul>
			
			<ul class="tag-list">
			<li class="">Cancer Therapy:</li>
				<li>
					<a class="label label-tag" href="#">tag</a>
				</li>
			</ul>
		</div>
	</header>
	<div class="item-content">
	<div class="take-home-message">
		<h3>TAKE-HOME MESSAGE</h3>
		<p>Results of this study of the ability of an electronic nose to recognize molecular patterns in the breath of asbestos-exposed patients vs controls suggest that these “breathprints” may serve as a biomarker for malignant mesothelioma.</p>
	</div>
		<h3>Abstract</h3>
<h4>Background:</h4>
<p>Malignant Pleural Mesothelioma (MPM) is a tumour of the surface cells of the pleura that is highly aggressive and mainly caused by asbestos exposure. Electronic noses capture the spectrum of exhaled volatile organic compounds (VOCs) providing a composite biomarker profile (breathprint).</p>

<h4>Objective:</h4>
<p>We tested the hypothesis that an electronic nose can discriminate exhaled air of patients with MPM from subjects with a similar long-term professional exposure to asbestos without MPM and from healthy controls.</p>

<h4>Methods:</h4>
<p>13 patients with a histology confirmed diagnosis of MPM (age 60.9±12.2 year), 13 subjects with certified, long-term professional asbestos exposure (age 67.2±9.8), and 13 healthy subjects without asbestos exposure (age 52.2±16.2) participated in a cross-sectional study. Exhaled breath was collected by a previously described method and sampled by an electronic nose (Cyranose 320). Breathprints were analyzed by canonical discriminant analysis on principal component reduction. Cross-validated accuracy (CVA) was calculated.</p>

<h4>Results:</h4>
<p>Breathprints from patients with MPM were separated from subjects with asbestos exposure (CVA: 80.8%, sensitivity 92.3%, specificity 85.7%). MPM was also distinguished from healthy controls (CVA: 84.6%). Repeated measurements confirmed these results.</p>

<h4>Conclusions:</h4>
<p>Molecular pattern recognition of exhaled breath can correctly distinguish patients with MPM from subjects with similar occupational asbestos exposure without MPM and from healthy controls. This suggests that breathprints obtained by electronic nose have diagnostic potential for MPM.</p>


<a href="#" class="btn">Access this article ></a>
<hr />
	</div>
	<footer class="footnotes panel">
	<h1>References:</h1>
		<ol class="footnote-list">
			<li>Scher, HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.Lancet. 2010 Apr 24;375(9724):1437-46.</li>
			<li>JS de Bono, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. [<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1014618">http://www.nejm.org/doi/full/10.1056/NEJMoa1014618</a>]</li>
			<li>JS de Bono, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol (Meeting Abstracts). May 2010 vol. 28 no. 15, suppl 4508. [<a href="http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30560">http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30560</a>]</li>
			<li>Parker C, et al. Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). Eur J Cancer. September 2011; 47(suppl2):3.</li>
		</ol>
	</footer>
<footer class="copyright">
<img class="logo" src="http://placehold.it/100x50"/>
<p>Copyright &copy; Elsevier Inc. All rights reserved.</p>
</footer>
</article>
</div><!--/.item-container-->

	</section><!--/[role="main"]-->
	<section id="sidebar" role="complementary">
		<div class="dashboard">
			<div class="component user-specialties">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">Specialties
							<a href="#" ><i class="icon-cog"></i></a>
						<li class="active"><a href="#">All</a></li>
						<li><a href="#">Hemotology</a></li>
						<li><a href="#">Urology</a></li>
					</ul>
				</nav>
			</div><!--/.component.user-specialties-->
			<div class="component user-topics">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">My Topics
							<a href="#" ><i class="icon-cog"></i></a>
						</li>
						<li class="active"><a href="#">All</a></li>
						<li><a href="#">Hemotology</a></li>
						<li><a href="#">Urology</a></li>
					</ul>
				</nav>
			</div><!--/.component.user-topics-->
			<div class="component user-lists">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">My Lists<a href="#" ><i class="icon-cog"></i></a></li>
					<li><a href="#">Custom List #1</a></li>
					<li><a href="#">Custom List #2</a></li>
					<li><a href="#">Custom List #3</a></li>
					</ul>
				</nav>
			</div><!--/.component.user-lists-->
			<div>
				<img src="http://placehold.it/200x200" /><p>Meet Our Experts Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.<p>
			</div>
		</div><!--/.sidebar-->
	</section><!--/.[role="complimentary"]-->
	</div><!--/.page-content-->
</div><!--/.container-->

	<!-- Included JS Files -->
	<script src="assets/js/libs/jquery.min.js"></script>
	<script src="assets/js/foundation/jquery.reveal.js"></script>
	<script src="assets/js/foundation/jquery.orbit-1.4.0.js"></script>
	<script src="assets/js/foundation/jquery.customforms.js"></script>
	<script src="assets/js/foundation/jquery.placeholder.min.js"></script>
	<script src="assets/js/foundation/jquery.tooltips.js"></script>

	<!-- <script src="javascripts/app.js"></script> -->
		<script src="assets/js/app.js"></script>
	  <script src="assets/js/foundation/jquery.offcanvas.js"></script>
		<script src="assets/js/mustache.js"></script>

	<!-- Mustache - homepage feed template -->
	<script>
	<!-- Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
		$.get('assets/mustache/feed-item.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.stream-container').html(html);
		});

	});
	<!-- Mustache - homepage recommended template -->
	$.getJSON('content/json/recommended.json', function(data) {
		$.get('assets/mustache/recommended.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.recommended').prepend(html);
		});

	});

	<!-- Mustache - homepage recommended template -->
	$.getJSON('content/json/recent.json', function(data) {
		$.get('assets/mustache/recent.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.recent').html(html);
		});

	});

	</script>

</body>
</html>